Molecular diagnostics are well-established in clinical medicine. Nonetheless, the markets for these tests remain one of the most attractive growth opportunities in the in vitro diagnostics industry.
Faster Test Results for Infection Lead to Safer and More Cost-Effective Hospitals The process of culture-based testing for microbes has been in common use for more than a century. In recent decades, ...
CRISPR gene editing and next-generation sequencing (NGS) have transformed clinical and life sciences research. CRISPR permits the selective targeting and editing of specific nucleotide sequences, with ...
Dealmaking was strong among molecular diagnostics (MDx) players during 2021 despite the continuation of the pandemic, with most merger and acquisition (M&A) transactions demonstrating either a pivot ...
To date, the limited efforts toward advancing cancer diagnostics in LMICs have focused on basic pathology services. Molecular diagnostics—now a standard part of cancer management in high-income ...
REDMOND, Wash.--(BUSINESS WIRE)--Anavasi Diagnostics, an NIH/RADx funded medical technology company developing novel molecular diagnostic testing for the point-of-care (POC) market, announced the Food ...
The point-of-care (POC) molecular diagnostics market is steadily expanding, with a compound annual growth rate (CAGR) of approximately 6%. This growth is fueled by a growing need for fast, ...
―Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results